Omnimmune Holdings Net Income
| OMMH Stock | USD 0.0001 0.00 0.000003% |
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Omnimmune Holdings, as well as the relationship between them.
Omnimmune Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Omnimmune Holdings' valuation are provided below:We have found eighty-two available trending fundamental ratios for Omnimmune Holdings, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Omnimmune Holdings recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to 785.70. Enterprise Value is estimated to decrease to about 1.1 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -1.6 M | -1.7 M | |
| Net Loss | -1.6 M | -1.7 M | |
| Net Loss | -1.6 M | -1.7 M | |
| Net Loss | (0.23) | (0.24) |
Omnimmune | Net Income | Build AI portfolio with Omnimmune Stock |
The Net Income trend for Omnimmune Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Omnimmune Holdings is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Omnimmune Holdings' Net Income Growth Pattern
Below is the plot of the Net Income of Omnimmune Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Omnimmune Holdings financial statement analysis. It represents the amount of money remaining after all of Omnimmune Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Omnimmune Holdings' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Omnimmune Holdings' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Omnimmune Net Income Regression Statistics
| Arithmetic Mean | (1,644,406) | |
| Coefficient Of Variation | (25.19) | |
| Mean Deviation | 194,831 | |
| Median | (1,761,268) | |
| Standard Deviation | 414,191 | |
| Sample Variance | 171.6B | |
| Range | 1.7M | |
| R-Value | (0.35) | |
| Mean Square Error | 160.6B | |
| R-Squared | 0.12 | |
| Significance | 0.17 | |
| Slope | (28,680) | |
| Total Sum of Squares | 2.7T |
Omnimmune Net Income History
Other Fundumenentals of Omnimmune Holdings
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Omnimmune Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Omnimmune Holdings is extremely important. It helps to project a fair market value of Omnimmune Stock properly, considering its historical fundamentals such as Net Income. Since Omnimmune Holdings' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Omnimmune Holdings' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Omnimmune Holdings' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Omnimmune introduce new products? Factors like these will boost the valuation of Omnimmune Holdings. Anticipated expansion of Omnimmune directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Omnimmune Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Omnimmune Holdings's market price often diverges from its book value, the accounting figure shown on Omnimmune's balance sheet. Smart investors calculate Omnimmune Holdings' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Omnimmune Holdings' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Omnimmune Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnimmune Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Omnimmune Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Omnimmune Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Omnimmune Holdings' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Omnimmune Holdings.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Omnimmune Holdings on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Omnimmune Holdings or generate 0.0% return on investment in Omnimmune Holdings over 90 days. Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company... More
Omnimmune Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Omnimmune Holdings' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Omnimmune Holdings upside and downside potential and time the market with a certain degree of confidence.
Omnimmune Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Omnimmune Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Omnimmune Holdings' standard deviation. In reality, there are many statistical measures that can use Omnimmune Holdings historical prices to predict the future Omnimmune Holdings' volatility.Omnimmune Holdings Backtested Returns
We have found three technical indicators for Omnimmune Holdings, which you can use to evaluate the volatility of the company. The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Omnimmune Holdings are completely uncorrelated.
Auto-correlation | 1.07 |
Perfect predictability
Omnimmune Holdings has perfect predictability. Overlapping area represents the amount of predictability between Omnimmune Holdings time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Omnimmune Holdings price movement. The serial correlation of 1.07 indicates that 107.0% of current Omnimmune Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.07 | |
| Spearman Rank Test | 0.64 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Omnimmune Operating Income
Operating Income |
|
Based on the recorded statements, Omnimmune Holdings reported net income of (1.76 Million). This is 100.52% lower than that of the Biotechnology sector and 102.51% lower than that of the Health Care industry. The net income for all United States stocks is 100.31% higher than that of the company.
Omnimmune Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omnimmune Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omnimmune Holdings could also be used in its relative valuation, which is a method of valuing Omnimmune Holdings by comparing valuation metrics of similar companies.Omnimmune Holdings is currently under evaluation in net income category among its peers.
Omnimmune Fundamentals
| Return On Asset | -20.76 | ||||
| Current Valuation | 31.38 K | ||||
| Shares Outstanding | 9.81 M | ||||
| Price To Earning | (0.02) X | ||||
| Price To Sales | 5,008 X | ||||
| Net Income | (1.76 M) | ||||
| Cash And Equivalents | 4.8 K | ||||
| Total Debt | 987.05 K | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0.61) X | ||||
| Cash Flow From Operations | (252.43 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | -0.18 | ||||
| Market Capitalization | 980 | ||||
| Total Asset | 31.43 K | ||||
| Retained Earnings | (21.1 M) | ||||
| Working Capital | (4.67 M) | ||||
| Current Asset | 44 K | ||||
| Current Liabilities | 4.71 M | ||||
| Net Asset | 31.43 K |
About Omnimmune Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Omnimmune Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omnimmune Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omnimmune Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Omnimmune Stock please use our How to Invest in Omnimmune Holdings guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is there potential for Biotechnology market expansion? Will Omnimmune introduce new products? Factors like these will boost the valuation of Omnimmune Holdings. Anticipated expansion of Omnimmune directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Omnimmune Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Omnimmune Holdings's market price often diverges from its book value, the accounting figure shown on Omnimmune's balance sheet. Smart investors calculate Omnimmune Holdings' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Omnimmune Holdings' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Omnimmune Holdings' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnimmune Holdings should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Omnimmune Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.